TARA: Net loss widened to $13.3M in Q3 2025 as R&D spending increased and clinical programs advanced

Q3 2025 saw increased R&D and G&A expenses, driving a net loss of $13.3M and a nine-month loss of $40.1M. Cash and equivalents stood at $133.6M, with ongoing clinical trials for TARA-002 and IV Choline Chloride advancing. Additional capital will be needed to support future operations.

Original document: Protara Therapeutics, Inc. [TARA] SEC 10-Q Quarterly Report — Nov. 10 2025